Drug Patents owned by Dexcel Pharma
1. List of Esomeprazole Magnesium drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10835488 | DEXCEL PHARMA | Stable orally disintegrating pharmaceutical compositions |
Dec, 2036
(13 years from now) | |
| US10076494 | DEXCEL PHARMA | Stable orally disintegrating pharmaceutical compositions |
Dec, 2036
(13 years from now) | |
Drugs and Companies using ESOMEPRAZOLE MAGNESIUM ingredient
Market Authorisation Date: 20 October, 2020
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL
ESOMEPRAZOLE MAGNESIUM family patents
3
United States
2
European Union
1
Israel
1
Australia
2. List of Hemady drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10537585 | DEXCEL PHARMA | Compositions comprising dexamethasone |
Dec, 2037
(14 years from now) | |
| US11304961 | DEXCEL PHARMA | Compositions comprising dexamethasone |
Dec, 2037
(14 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Oct 3, 2026 |
Drugs and Companies using DEXAMETHASONE ingredient
Market Authorisation Date: 03 October, 2019
Treatment: A method of treating adults with multiple myeloma using dexamethasone in combination with an anti-myeloma product
Dosage: TABLET;ORAL
HEMADY family patents
2
United States
1
Israel
3. List of Lansoprazole drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11077055 | DEXCEL PHARMA | Orally disintegrating compositions |
Apr, 2036
(13 years from now) | |
Drugs and Companies using LANSOPRAZOLE ingredient
Market Authorisation Date: 07 June, 2016
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL
LANSOPRAZOLE family patents
4
United States
2
Israel
1
European Union
4. List of Omeprazole drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9023391 | DEXCEL PHARMA | Stable benzimidazole formulation |
Aug, 2025
(2 years from now) | |
| US10835488 | DEXCEL PHARMA | Stable orally disintegrating pharmaceutical compositions |
Dec, 2036
(13 years from now) | |
| US10076494 | DEXCEL PHARMA | Stable orally disintegrating pharmaceutical compositions |
Dec, 2036
(13 years from now) | |
Drugs and Companies using OMEPRAZOLE ingredient
Market Authorisation Date: 04 December, 2007
Treatment: NA
Dosage: TABLET, DELAYED RELEASE;ORAL
OMEPRAZOLE family patents
8
United States
4
Israel
3
European Union
2
Australia
1
Germany
1
Austria
1
Spain
1
Canada
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic